<DOC>
	<DOCNO>NCT02287896</DOCNO>
	<brief_summary>The aim study assess pharmacokinetic profile Roledumab 300μg IM / IV RhDnegative pregnant woman carry RhD-positive foetus . And assess safety Roledumab RhD-negative pregnant woman RhD-positive foetus newborn . In addition efficacy Roledumab 300μg IM IV prevent RhD alloimmunisation RhDnegative pregnant woman carry RhD-positive foetus immunogenicity Roledumab assess .</brief_summary>
	<brief_title>Pharmacokinetics Safety Roledumab , RhD-negative Pregnant Women Carrying RhD-positive Foetus</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Signed date informed consent form provide subject prior proceeding studyrelated procedure , At least 18 year old , Pregnancy 12 27 week gestational age confirm early ultrasound , Pregnant RhDnegative woman carry RhDpositive foetus confirm noninvasive foetal RhD genotyping test Negative serology : hepatitis B C , HIV ( 1 2 ) , except positive result due vaccination , Covered healthcare insurance accordance local requirement . RhD alloimmunised subject , Positive ADA Test , Multiple foetuses , Occurrence document potential sensitizing event pregnancy antenatal IMP administration , Prior administration antiRhD immunoglobulin current pregnancy , Known clinically relevant maternal foetal abnormality ( e.g. , determine ultrasound genetic testing ) , placenta previa , History anaphylactic severe systemic reaction immunoglobulin origin , Current diagnosis immune disease treatment could impair safety and/or efficacy evaluation Roledumab study . These disease : All immune deficiency , particularly require IVIg supplementation systemic treatment / connective tissue autoimmune disease ( e.g. , systemic lupus erythematosus , antiphospholipid syndrome , Sjögren 's syndrome , rheumatoid arthritis , ankylose spondylarthritis ) require systemic immunosuppressive treatment / allergic inflammatory disease require systemic immunosuppressive treatment . Clinically significant medical history contraindicate participation study accord judgment Investigator Sponsor , Clinically significant laboratory ( haematology , blood chemistry , urinalysis ) parameter , Transfusion RhDpositive blood blood derive product within 6 month prior enrolment , Anticipated poor compliance study procedure , Subject within exclusion period participation clinical study , For IM arm , subject coagulation disorder contraindicate intramuscular injection ( patient still consider IV arm )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RhD-negative pregnant woman</keyword>
	<keyword>anti-RhD antibody</keyword>
</DOC>